噻托溴铵联合沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期的疗效研究  

Study the efficacy of tiotropium bromide combined with salmeterol fluticasone in the treatment of acute exacerbation of chronic obstructive pulmonary disease

作　　者：解传宏 XIE Chuan-hong(Department of Respiratory Medicine,Nuclear Industry General Hospital of Xingcheng Health Industry Group,Xingcheng 125100,China)

机构地区：[1]辽宁省兴城市健康产业集团核工业总医院呼吸内科,125100

出　　处：《中国现代药物应用》2023年第3期105-107,共3页Chinese Journal of Modern Drug Application

摘　　要：目的 分析噻托溴铵联合沙美特罗替卡松治疗慢性阻塞性肺疾病急性加重期的疗效。方法 50例慢性阻塞性肺疾病急性加重期患者,随机分为对照组和观察组,每组25例。对照组采用沙美特罗替卡松治疗,观察组则在对照组的基础上联合噻托溴铵治疗。比较两组患者治疗前后第1秒用力呼气容积、肺活量、呼气峰值流速、炎症指标[肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)、白细胞介素6(IL-6)]水平以及临床疗效。结果 治疗后,观察组患者第1秒用力呼气容积(2.72±0.32)L、肺活量(3.53±0.61)L、呼气峰值流速(2.52±0.34)L/s均高于对照组的(1.63±0.69)L、(2.72±0.62)L、(1.43±0.23)L/s,差异均具有统计学意义(P<0.05)。治疗后,观察组患者TNF-α(1.54±0.21)ng/ml、hs-CRP(7.01±1.02)mg/L、IL-6(61.46±2.16)pg/ml均低于对照组的(2.61±0.28)ng/ml、(9.31±1.56)mg/L、(121.57±2.11)pg/ml,差异均具有统计学意义(P<0.05)。观察组临床总有效率96.00%高于对照组的72.00%,差异具有统计学意义(P<0.05)。结论 沙美特罗替卡松与噻托溴铵对于慢性阻塞性肺疾病急性加重期的效果确切,可控制肺部炎症,改善肺功能,值得推广。Objective To analyze the efficacy of tiotropium bromide combined with salmeterol fluticasone in the treatment of acute exacerbation of chronic obstructive pulmonary disease. Methods A total of 50 patients with acute exacerbation of chronic obstructive pulmonary disease were randomly divided into a control group and an observation group, with 25 cases in each group. The control group was treated with salmeterol fluticasone, while the observation group was treated with tiotropium fluticasone on the basis of the control group. Both groups were compared in terms of forced expiratory volume in one second, vital capacity, peak expiratory flow rate, inflammatory indexes [tumor necrosis factor-α(TNF-α), high-sensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6)] before and after treatment, and clinical efficacy. Results After treatment, the forced expiratory volume in one second(2.72±0.32) L, vital capacity(3.53±0.61) L, and peak expiratory flow rate(2.52±0.34) L/s in the observation group were higher than(1.63±0.69) L,(2.72±0.62) L, and(1.43±0.23) L/s in the control group, and the differences were statistically significant(P< 0.05). After treatment, the TNF-α(1.54±0.21) ng/ml, hs-CRP(7.01±1.02) mg/L, and IL-6(61.46±2.16) pg/ml in the observation group were lower than(2.61±0.28) ng/ml,(9.31±1.56) mg/L, and(121.57±2.11) pg/ml in the control group, and the differences were all statistically significant(P<0.05). The total clinical effective rate 96.00% in the observation group was higher than 72.00% in the control group, and the difference was statistically significant(P<0.05). Conclusion Salmeterol fluticasone in combination with tiotropium bromide has definite effects on acute exacerbation of chronic obstructive pulmonary disease, which can control pulmonary inflammation and improve lung function, and is worthy of promotion.

关 键 词：噻托溴铵 沙美特罗替卡松 慢性阻塞性肺疾病急性加重期 疗效 

分 类 号：R563.9[医药卫生—呼吸系统]